Data gathered: November 27
AI Stock Analysis - Janux Therapeutics (JANX)
Analysis generated July 18, 2024. Powered by Chat GPT.
Janux Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapies for the treatment of cancer. The company's proprietary technology platform leverages its expertise in protein engineering and immunology to create novel therapies aimed at transforming cancer treatment. Janux Therapeutics is committed to delivering novel therapeutic solutions to patients who suffer from cancer.
Stock Alerts - Janux Therapeutics (JANX)
 |
Janux Therapeutics | November 22 Price is up by 5.4% in the last 24h. |
|
Janux Therapeutics | November 21 Price is down by -5.6% in the last 24h. |
|
Janux Therapeutics | November 15 Price is down by -5.2% in the last 24h. |
|
Janux Therapeutics | November 11 Price is down by -5.1% in the last 24h. |
Alternative Data for Janux Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 11 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 44 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 683 | Sign up | Sign up | Sign up |
| Twitter Followers | 97 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 62 | Sign up | Sign up | Sign up |
| Linkedin Employees | 78 | Sign up | Sign up | Sign up |
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
| Price | $46.39 |
| Target Price | Sign up |
| Volume | 472,480 |
| Market Cap | $2.56B |
| Year Range | $35.12 - $64.78 |
| Dividend Yield | 0% |
| Analyst Rating | 89% buy |
| Industry | Biotechnology |
In the news
 |
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analysts at Leerink PartnersNovember 25 - ETF Daily News |
|
Janux Therapeutics (NASDAQ:JANX) Upgraded to Strong-Buy at Leerink PartnrsNovember 24 - ETF Daily News |
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion StudiesNovember 24 - Finnhub |
|
 |
Janux Therapeutics initiated with an Outperform at LeerinkNovember 22 - Yahoo |
 |
Janux Therapeutics: Believable Theory, Strong Early Data, Needs ConfirmationNovember 18 - SeekingAlpha |
 |
Janux Therapeutics (NASDAQ:JANX) Earns “Outperform” Rating from William BlairNovember 16 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.3M | 18M | -16M | -28M | -36M | -0.510 |
| Q2 '24 | 9.7M | 7.8M | 1.9M | -6M | -13M | -0.110 |
| Q1 '24 | 2.1M | 7.3M | -5.3M | -15M | -20M | -0.300 |
| Q4 '23 | 3.4M | 6.4M | -3M | -12M | -16M | -0.250 |
| Q3 '23 | 3.3M | 6.4M | -3.1M | -12M | -16M | -0.250 |
Insider Transactions View All
| Campbell David Alan filed to sell 282,054 shares at $53.9. October 30 '24 |
| Campbell David Alan filed to sell 293,157 shares at $53.2. October 30 '24 |
| Lichter Jay filed to sell 506,278 shares at $51.2. October 18 '24 |
| Lichter Jay filed to sell 2,613,623 shares at $51.2. October 18 '24 |
| Lichter Jay filed to sell 2,668,592 shares at $51.2. October 18 '24 |
Similar companies
Read more about Janux Therapeutics (JANX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Janux Therapeutics?
The Market Cap of Janux Therapeutics is $2.56B.
What is the current stock price of Janux Therapeutics?
Currently, the price of one share of Janux Therapeutics stock is $46.39.
How can I analyze the JANX stock price chart for investment decisions?
The JANX stock price chart above provides a comprehensive visual representation of Janux Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Janux Therapeutics shares. Our platform offers an up-to-date JANX stock price chart, along with technical data analysis and alternative data insights.
Does JANX offer dividends to its shareholders?
As of our latest update, Janux Therapeutics (JANX) does not offer dividends to its shareholders. Investors interested in Janux Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Janux Therapeutics?
Some of the similar stocks of Janux Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.